- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06410222
Predictive Models for the Treatment of Recurrent Herpes Zoster Neuralgia Following Spinal Cord Electrical Stimulation.
Risk Factor Analysis and Predictive Models for the Treatment of Recurrent Herpes Zoster Neuralgia Following Short-course Spinal Cord Electrical Stimulation: a Multicenter, Retrospective, Observational Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Shingles is a neuropathic disease caused by varicella-herpes virus(VZV) invading nerves and accompanying pain. About 3~5/1000 people suffer from shingles every year in the world, and 2.9~5.8/1000 people over the age of 50 in China suffer from shingles every year, with an annual growth rate of 2.5~5.0%. If acute herpes zoster can not be treated effectively, it will be transformed into postherpetic neuralgia (PHN), patients will suffer long-term knife, needle, burning pain as well as hyperalgesia, touch induced pain and skin paresthesia, which seriously affect the daily life of patients. It also causes a huge social and economic burden.Currently, the treatment of postherpetic neuralgia (PHN) includes medication and minimally invasive interventional therapy. The European Neurological Association has proposed guidelines for first - and second-line drug treatment of herpes zoster neuralgia with level A evidence. At the same time, some patients are relieved by interventional therapy, such as injection therapy (local injection, peripheral nerve block, stellar ganglion block), nerve stimulation therapy (percutaneous electrical nerve stimulation, peripheral nerve stimulation, pulsed radiofrequency), spinal cord stimulation (SCS), and spinal dorsal horn ganglion destruction.
In 1976, spinal cord stimulation (SCS) was first used to treat patients with nociceptive pain. It is to place the stimulation electrode around the diseased nerve for a certain time, frequency, and voltage adjustment, so as to relieve pain. At present, spinal cord stimulation (SCS) has been widely used and studied in the treatment of postherpetic neuralgia (PHN) at home and abroad, and its mechanism of action may be related to the "gate control theory of pain" : in the dorsal horn of the spinal cord, α fiber can inhibit the pain signal transmitted by C fiber, and spinal cord stimulation (SCS) may regulate the transmission of pain signal through this mechanism. At the same time, spinal cord stimulation (SCS) can also affect the levels of gamma-aminobutyric acid and adenosine in the dorsal horn, thereby reducing neuropathic pain.In patients with herpes zoster neuralgia treated with spinal cord stimulation (SCS), some patients have satisfactory pain relief after surgery, but some patients have pain symptoms again some time after surgery. The reason for this difference in treatment effect is not clear. Therefore, this study intends to retrospectively analyze the clinical data of patients with and the risk factors for recurrence after treatment, and then construct a prognostic prediction model to provide evidence and reference for clinical treatment of postherpetic neuralgia (PHN).
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Tongji Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Diagnostic criteria for PHN:
- In this study, the duration of herpes zoster eruption with pain was greater than or greater than 1 month.
Description
Inclusion Criteria:
- Age ≥18 years old.
- NRS score ≥4 points.
- The pain NRS of previous shingles area treated with SCS was ≤3, and the pain NRS was > 4 after recurrence.
Exclusion Criteria:
- Serious cardiovascular and cerebrovascular diseases, such as heart failure, intracranial aneurysm, hypertension (high risk, very high risk).
- Epilepsy, suffering from mental illness.
- And patients who were lost to follow-up.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain recurrence
Time Frame: up to 1 year
|
The diagnostic criteria for pain recurrence at the site of postherpetic neuralgia were Numeric Rating Scales(NRS) score > 4.
|
up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The time of electrodes placed in patients
Time Frame: immediately after the surgery
|
record the time of spinal cord stimulation in spinal of patients.
|
immediately after the surgery
|
Surgical safety indicators
Time Frame: after the surgery 3 days
|
record the safety indicators during the spinal cord stimulation surgical ,include the displacement of electrodes and so on.
|
after the surgery 3 days
|
numeric rating scale(NRS)
Time Frame: After spinal cord stimulation surgical 1 year
|
The NRS pain Score is an exponential scale that uses 0 to 10 to represent different levels of pain, 0 being painless and 10 being severe, and asks the patient how bad the pain is, or to circle a number that best represents their pain.
|
After spinal cord stimulation surgical 1 year
|
numeric rating scale(NRS)
Time Frame: Day 1 in the hospital
|
The NRS pain Score is an exponential scale that uses 0 to 10 to represent different levels of pain, 0 being painless and 10 being severe, and asks the patient how bad the pain is, or to circle a number that best represents their pain.
|
Day 1 in the hospital
|
numeric rating scale(NRS)
Time Frame: the day before the spinal cord stimulation surgical
|
The NRS pain Score is an exponential scale that uses 0 to 10 to represent different levels of pain, 0 being painless and 10 being severe, and asks the patient how bad the pain is, or to circle a number that best represents their pain.
|
the day before the spinal cord stimulation surgical
|
C-reactive protein
Time Frame: Day 1 in the hospital
|
An according to early infection stricture in serum.When CRP>20mg/l is considered abnormally level .
|
Day 1 in the hospital
|
Albumin
Time Frame: Day 1 in the hospital
|
It is a protein that is found in many animal tissues and serum.The normal range 35-50g/L.
|
Day 1 in the hospital
|
diastolic blood pressure
Time Frame: Day 1 in the hospital
|
An indicator in blood pressure measurement that indicates the pressure of the heart's arterial blood against the vessel walls during diastole.
It is usually measured in millimeters of mercury (mmHg).
|
Day 1 in the hospital
|
systolic blood pressure
Time Frame: Day 1 in the hospital
|
A type of blood pressure that refers to the pressure of blood against the artery walls when the heart contracts.
It is often used as a measure of cardiovascular health(mmHg).
|
Day 1 in the hospital
|
red blood cell count
Time Frame: Day 1 in the hospital
|
The red blood cell count (RBC count) is a measurement of the number of red blood cells present in a microliter (μL) of blood.For males: 4.5 to 5.9 million cells per microliter (μL) of blood.For females: 4.0 to 5.2 million cells per microliter (μL) of blood.
|
Day 1 in the hospital
|
eosinophilic granulocyte
Time Frame: Day 1 in the hospital
|
Eosinophils are a type of white blood cell, specifically a subtype of granulocyte, characterized by the presence of eosinophilic granules in their cytoplasm.
The normal range for eosinophils is typically between 0% and 6% of the total white blood cell count, though this can vary slightly depending on the laboratory's reference values and the individual's age and health status.
|
Day 1 in the hospital
|
erythrocyte sedimentation rate (ESR)
Time Frame: Day 1 in the hospital
|
the sedimentation rate or "sed rate," is a test that measures the rate at which red blood cells (erythrocytes) settle in a tube of blood over a specific period of time.
|
Day 1 in the hospital
|
hemoglobin
Time Frame: Day 1 in the hospital
|
Hemoglobin is a protein found in red blood cells that is responsible for transporting oxygen from the lungs to the rest of the body's tissues and organs, and for carrying carbon dioxide back to the lungs for exhalation.The normal range of hemoglobin levels for adult males: 13.8 to 17.2 grams per deciliter (g/dL).
adult females: 12.1 to 15.1 g/dL
|
Day 1 in the hospital
|
neutrophilic granulocyte percentage
Time Frame: Day 1 in the hospital
|
The neutrophilic granulocyte percentage, often referred to simply as neutrophil percentage or neutrophil count, is a measure of the proportion of neutrophils in the total white blood cell count.a
normal neutrophil percentage typically falls within the range of approximately 40% to 75% of the total white blood cell count.
|
Day 1 in the hospital
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TJ-JRB202402013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post Herpetic Neuralgia
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPost Herpetic NeuralgiaUnited States, Colombia, South Africa, Hong Kong, Ukraine, Bulgaria, Croatia, India, Sweden, Czechia, Denmark, Germany, Poland, Russian Federation, Serbia, Slovakia, Taiwan
-
Bial - Portela C S.A.Terminated
-
Grünenthal GmbHCompletedPost Herpetic Neuralgia
-
Novartis PharmaceuticalsTerminatedPost-herpetic NeuralgiaAustralia, Taiwan, Germany, France, Portugal, Czechia, United Kingdom, Hungary, Spain, Slovakia, Japan, Canada, Denmark, Norway, Austria, Belgium, Poland, Italy, Korea, Republic of
-
Convergence PharmaceuticalsCompletedPost-herpetic NeuralgiaSouth Africa
-
Odense University HospitalCompletedPost Herpetic NeuralgiaDenmark
-
DepomedCompletedPost Herpetic NeuralgiaUnited States
-
NeurAxon Inc.CompletedPost Herpetic NeuralgiaUnited States, Canada
-
University of Sao PauloCompletedPost-herpetic Neuralgia
-
Bristol-Myers SquibbCompleted
Clinical Trials on Recurrence after undergo spinal cord stimulation
-
Barts & The London NHS TrustBoston Scientific CorporationUnknown
-
University of British ColumbiaProvidence Health & Services; International Spinal Research Trust; International...RecruitingSexual Dysfunction, Physiological | Spinal Cord Injuries | Neurogenic Bowel | Neurogenic Bladder | Spinal Cord StimulationCanada
-
St. Olavs HospitalNorwegian University of Science and TechnologyRecruiting
-
Universitair Ziekenhuis BrusselMedtronicCompletedFailed Back Surgery SyndromeBelgium
-
Imperial College LondonRecruitingParkinson Disease | Freezing of GaitUnited Kingdom
-
University of Sao Paulo General HospitalTerminatedParkinson Disease | Gait Disorders, NeurologicBrazil
-
James J. Peters Veterans Affairs Medical CenterRecruitingOrthostatic HypotensionUnited States
-
Stanford UniversityActive, not recruitingChronic PainUnited States
-
Boston Scientific CorporationTerminatedPain | Peripheral Neuropathy | Diabetic NeuropathyUnited States
-
University of CalgaryInternational Collaboration on Repair DiscoveriesUnknownSpinal Cord Injuries | Autonomic Dysreflexia | Orthostatic Hypotension, DysautonomicCanada